98474-97-6

Upstream product

• 27607-77-8 trimethylsilyl trifluoromethanesulfonate 
• 14352-61-5 methyl cyclohexylacetate 

Downstream Products

• 144409-81-4 3-Cyclohexyl-2-methoxy-2-trimethylsilanyloxy-cyclobutanecarbonitrile 
• 125816-72-0 4-Cyano-2-cyclohexyl-4-trimethylsilanyl-butyric acid methyl ester 
• 144381-32-8 methyl 4-cyano-2-cyclohexylbutanoate 
• 848758-88-3 4,6-dichloro-3-(2-cyclohexyl-2-methoxycarbonyl-vinyl)-1H-indole-2-carboxylic acid ethyl ester 
• 848758-90-7 4,6-dichloro-3-(2-cyclohexyl-2-methoxycarbonyl-vinyl)-1H-indole-2-carboxylic acid 
• 1026289-06-4 4,6-dichloro-3-(2-cyclohexyl-1-hydroxy-2-methoxycarbonyl-ethyl)-1H-indole-2-carboxylic acid ethyl ester 
• 120780-34-9 (Z)-ethyl 4-carbomethoxy-4-cyclohexyl-2-butenoate 
• 120780-33-8 (E)-ethyl 4-carbomethoxy-4-cyclohexyl-2-butenoate 

Relevant academic research and scientific papers

CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2- arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-Aminophenyl)-2- carboxyvinyl]-4,6-dichloro-1H-indole-2-carboxylic acid, a potent selective glycine-site NMDA receptor antagonist

(E)-3-(2-Carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid, 1, is a potent and selective antagonist of the glycine site of the N-methyl-D-aspartate (NMDA) receptor. Using 3D comparative molecular field analysis (CoMFA) to guide the synthetic effort, a series of aryl diacid analogues of 1 were synthesized to optimize in vivo potency, duration of action, and binding activity. It was found that the incorporation of a substituted aromatic with an electron withdrawing group or a heterocyclic group at the 2-position of the 3-propenyl moiety of 1 gave compounds with better affinity and potency in the murine stroke model. Ultimately this led to the discovery of 3-[2-(3-aminophenyl)-2-carboxyvinyl]-4,6-dichloro-1H-indole-2-carboxylic acid, 19, as a new potent selective glycine-site NMDA receptor antagonist.